Abstract:The NLRP3 inflammasome is a critical component of innate immunity, which defends internal and external threats. However, inappropriate activation of the NLRP3 inflammasome induces various human diseases. In this study, we discovered and synthesized a series of tetrahydroquinoline inhibitors of NLRP3 inflammasome. Among these analogues, compound 6 exhibited optimal NLRP3 inhibitory activity. In vitro studies indicated that compound 6 directly bound to the NACHT domain of NLRP3 but not to protein pyrin domain (PYD) or LRR domain, inhibited NLRP3 ATPase activity, and blocked ASC oligomerization, thereby inhibiting NLRP3 inflammasome assembly and activation. Compound 6 specifically inhibited the NLRP3 inflammasome activation, but had no effect on the activation of NLRC4 or AIM2 inflammasomes. Furthermore, in the dextran sulfate sodium (DSS)-induced colitis mouse model, compound 6 exhibited significant anti-inflammatory activity through inhibiting NLRP3 inflammasome in vivo. Therefore, our study provides a potent NLRP3 inflammasome inhibitor, which deserves further structural optimization as a novel therapeutic candidate for NLRP3-driven diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01924?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01924</a>.1H NMR, 13C NMR, and HPLC spectra analysis of all synthetic compounds; amino acid sequences of NLRP3 PYD domain, NACHT domain, and LRR domain; pharmacophore generation; pharmacophore and docking screening; small molecules in training set and testing set; and the activity tests of selected ligands (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_002.csv">CSV</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_003.pdf">PDF</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_004.xls">XLS</a>)This article has not yet been cited by other publications.

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis

Synthesis and Anti-Inflammatory Bowel Disease Activity of Pterostilbene Derivatives

Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis

Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors

Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis.

Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization

Discovery of Autophagy-tethering Compounds As Potent NLRP3 Degraders for IBD Immunotherapy

Discovery of novel N2-indazole derivatives as phosphodiesterase 4 inhibitors for the treatment of inflammatory bowel disease

Discovery, Total Synthesis, and Anti‐inflammatory Evaluation of Naturally Occurring Naphthopyrone‐Macrolide Hybrids as Potent NLRP3 Inflammasome Inhibitors

Synthesis and pharmacological validation of fluorescent diarylsulfonylurea analogues as NLRP3 inhibitors and imaging probes

Design, synthesis and biological evaluation of sulfonylurea derivatives as NLRP3 inflammasome inhibitors

Synthesis and Biological Evaluation of Novel Benzimidazole Derivatives and Analogs Targeting the NLRP3 Inflammasome

A Novel Benzo[d]imidazole Derivate Prevents the Development of Dextran Sulfate Sodium-Induced Murine Experimental Colitis Via Inhibition of NLRP3 Inflammasome.

Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome

Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen

Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity

Discovery of Novel Oridonin Sulfamide Derivatives as Potent NLRP3 Inhibitors by a Visible-Light Photocatalysis-Enabled Peripheral Editing

A novel sorbicillinoid compound as a potent anti-inflammation agent through inducing NLRP3 protein degradation